702 related articles for article (PubMed ID: 30288767)
21. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
Ciardullo S; Perseghin G
Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
[TBL] [Abstract][Full Text] [Related]
22. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
23. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
24. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.
Mansour A; Mohajeri-Tehrani MR; Samadi M; Gerami H; Qorbani M; Bellissimo N; Poustchi H; Hekmatdoost A
Acta Diabetol; 2019 Nov; 56(11):1199-1207. PubMed ID: 31197470
[TBL] [Abstract][Full Text] [Related]
26. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
[TBL] [Abstract][Full Text] [Related]
27. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.
Sun DQ; Ye FZ; Kani HT; Yang JR; Zheng KI; Zhang HY; Targher G; Byrne CD; Chen YP; Yuan WJ; Yilmaz Y; Zheng MH
Diabetes Metab; 2020 Sep; 46(4):288-295. PubMed ID: 31786360
[TBL] [Abstract][Full Text] [Related]
28. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
29. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.
Wong VW; Chu WC; Wong GL; Chan RS; Chim AM; Ong A; Yeung DK; Yiu KK; Chu SH; Woo J; Chan FK; Chan HL
Gut; 2012 Mar; 61(3):409-15. PubMed ID: 21846782
[TBL] [Abstract][Full Text] [Related]
31. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
[TBL] [Abstract][Full Text] [Related]
32. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
Singh A; Le P; Lopez R; Alkhouri N
Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
[TBL] [Abstract][Full Text] [Related]
33. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
[TBL] [Abstract][Full Text] [Related]
34. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD).
Tovo CV; Villela-Nogueira CA; Leite NC; Panke CL; Port GZ; Fernandes S; Buss C; Coral GP; Cardoso AC; Cravo CM; Calçado FL; Rezende GFM; Ferreira FC; Araujo-Neto JM; Perez RM; Moraes-Coelho HS; de Mattos AA
Ann Hepatol; 2019; 18(3):445-449. PubMed ID: 31031166
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
[TBL] [Abstract][Full Text] [Related]
36. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
[TBL] [Abstract][Full Text] [Related]
37. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
[TBL] [Abstract][Full Text] [Related]
38. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
39. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
[TBL] [Abstract][Full Text] [Related]
40. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
